<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20230928203712&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.17.9.post6+86293ac&amp;utm_source=Chrome&amp;utm_medium=rss&amp;ff=20230928203712&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.17.9.post6+86293ac)</generator>
<language>en</language>
<lastbuilddate>Fri, 29 Sep 2023 00:37:13 +0000</lastbuilddate>
<pubDate>Thu, 28 Sep 2023 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>In This Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37769047/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 29;133(8):655. doi: 10.1161/RES.0000000000000634. Epub 2023 Sep 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37769047/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37769047</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000634>10.1161/RES.0000000000000634</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37769047</guid>
<pubDate>Thu, 28 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>In This Issue</dc:title>
<dc:identifier>pmid:37769047</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000634</dc:identifier>
</item>
<item>
<title>Meet the First Authors</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37769046/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2023 Sep 29;133(8):656-657. doi: 10.1161/RES.0000000000000635. Epub 2023 Sep 28.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37769046/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37769046</a> | DOI:<a href=https://doi.org/10.1161/RES.0000000000000635>10.1161/RES.0000000000000635</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37769046</guid>
<pubDate>Thu, 28 Sep 2023 06:00:00 -0400</pubDate>
<dc:date>2023-09-28</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Meet the First Authors</dc:title>
<dc:identifier>pmid:37769046</dc:identifier>
<dc:identifier>doi:10.1161/RES.0000000000000635</dc:identifier>
</item>
<item>
<title>Food Is Medicine: A Presidential Advisory From the American Heart Association</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37767686/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>Unhealthy diets are a major impediment to achieving a healthier population in the United States. Although there is a relatively clear sense of what constitutes a healthy diet, most of the US population does not eat healthy food at rates consistent with the recommended clinical guidelines. An abundance of barriers, including food and nutrition insecurity, how food is marketed and advertised, access to and affordability of healthy foods, and behavioral challenges such as a focus on immediate...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2023 Sep 28. doi: 10.1161/CIR.0000000000001182. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Unhealthy diets are a major impediment to achieving a healthier population in the United States. Although there is a relatively clear sense of what constitutes a healthy diet, most of the US population does not eat healthy food at rates consistent with the recommended clinical guidelines. An abundance of barriers, including food and nutrition insecurity, how food is marketed and advertised, access to and affordability of healthy foods, and behavioral challenges such as a focus on immediate versus delayed gratification, stand in the way of healthier dietary patterns for many Americans. Food Is Medicine may be defined as the provision of healthy food resources to prevent, manage, or treat specific clinical conditions in coordination with the health care sector. Although the field has promise, relatively few studies have been conducted with designs that provide strong evidence of associations between Food Is Medicine interventions and health outcomes or health costs. Much work needs to be done to create a stronger body of evidence that convincingly demonstrates the effectiveness and cost-effectiveness of different types of Food Is Medicine interventions. An estimated 90% of the $4.3 trillion annual cost of health care in the United States is spent on medical care for chronic disease. For many of these diseases, diet is a major risk factor, so even modest improvements in diet could have a significant impact. This presidential advisory offers an overview of the state of the field of Food Is Medicine and a road map for a new research initiative that strategically approaches the outstanding questions in the field while prioritizing a human-centered design approach to achieve high rates of patient engagement and sustained behavior change. This will ideally happen in the context of broader efforts to use a health equity-centered approach to enhance the ways in which our food system and related policies support improvements in health.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37767686/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37767686</a> | DOI:<a href=https://doi.org/10.1161/CIR.0000000000001182>10.1161/CIR.0000000000001182</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37767686</guid>
<pubDate>Thu, 28 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Kevin G Volpp</dc:creator>
<dc:creator>Seth A Berkowitz</dc:creator>
<dc:creator>Shreela V Sharma</dc:creator>
<dc:creator>Cheryl A M Anderson</dc:creator>
<dc:creator>LaPrincess C Brewer</dc:creator>
<dc:creator>Mitchell S V Elkind</dc:creator>
<dc:creator>Christopher D Gardner</dc:creator>
<dc:creator>Julie E Gervis</dc:creator>
<dc:creator>Robert A Harrington</dc:creator>
<dc:creator>Mario Herrero</dc:creator>
<dc:creator>Alice H Lichtenstein</dc:creator>
<dc:creator>Mark McClellan</dc:creator>
<dc:creator>Jen Muse</dc:creator>
<dc:creator>Christina A Roberto</dc:creator>
<dc:creator>Justin P V Zachariah</dc:creator>
<dc:creator>American Heart Association</dc:creator>
<dc:date>2023-09-28</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Food Is Medicine: A Presidential Advisory From the American Heart Association</dc:title>
<dc:identifier>pmid:37767686</dc:identifier>
<dc:identifier>doi:10.1161/CIR.0000000000001182</dc:identifier>
</item>
<item>
<title>Reply: Cardiac Remodeling in Aortic Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758444/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):e125. doi: 10.1016/j.jacc.2023.07.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758444/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758444</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.022>10.1016/j.jacc.2023.07.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758444</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Maan Malahfji</dc:creator>
<dc:creator>Duc T Nguyen</dc:creator>
<dc:creator>Edward A Graviss</dc:creator>
<dc:creator>Dipan J Shah</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Reply: Cardiac Remodeling in Aortic Regurgitation</dc:title>
<dc:identifier>pmid:37758444</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.022</dc:identifier>
</item>
<item>
<title>Left Ventricular Remodeling in Aortic Regurgitation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758443/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):e123. doi: 10.1016/j.jacc.2023.06.049.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758443/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758443</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.049>10.1016/j.jacc.2023.06.049</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758443</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ramdas G Pai</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Left Ventricular Remodeling in Aortic Regurgitation</dc:title>
<dc:identifier>pmid:37758443</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.049</dc:identifier>
</item>
<item>
<title>Bicuspid Aortic Valve: An Anomaly to Be Reckoned With</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758442/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):e121. doi: 10.1016/j.jacc.2023.06.050.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758442/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758442</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.06.050>10.1016/j.jacc.2023.06.050</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758442</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Bo Liu</dc:creator>
<dc:creator>Xuan Jiang</dc:creator>
<dc:creator>Tianxiang Gu</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Bicuspid Aortic Valve: An Anomaly to Be Reckoned With</dc:title>
<dc:identifier>pmid:37758442</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.06.050</dc:identifier>
</item>
<item>
<title>Durable Mechanical Circulatory Support: JACC Scientific Statement</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758441/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>Despite advances in medical therapy for patients with stage C heart failure (HF), survival for patients with advanced HF is &lt;20% at 5 years. Durable left ventricular assist device (dLVAD) support is an important treatment option for patients with advanced HF. Innovations in dLVAD technology have reduced the risk of several adverse events, including pump thrombosis, stroke, and bleeding. Average patient survival is now similar to that of heart transplantation at 2 years, with 5-year dLVAD...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1464-1481. doi: 10.1016/j.jacc.2023.07.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Despite advances in medical therapy for patients with stage C heart failure (HF), survival for patients with advanced HF is &lt;20% at 5 years. Durable left ventricular assist device (dLVAD) support is an important treatment option for patients with advanced HF. Innovations in dLVAD technology have reduced the risk of several adverse events, including pump thrombosis, stroke, and bleeding. Average patient survival is now similar to that of heart transplantation at 2 years, with 5-year dLVAD survival now approaching 60%. Unfortunately, greater adoption of dLVAD therapy has not been realized due to delayed referral of patients to advanced HF centers, insufficient clinician knowledge of contemporary dLVAD outcomes (including gains in quality of life), and deprioritization of patients with dLVAD support waiting for heart transplantation. Despite these challenges, novel devices are on the horizon of clinical investigation, offering smaller size, permitting less invasive surgical implantation, and eliminating the percutaneous lead for power supply.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758441/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758441</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.019>10.1016/j.jacc.2023.07.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758441</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Ryan J Tedford</dc:creator>
<dc:creator>Marzia Leacche</dc:creator>
<dc:creator>Angela Lorts</dc:creator>
<dc:creator>Stavros G Drakos</dc:creator>
<dc:creator>Francis D Pagani</dc:creator>
<dc:creator>Jennifer Cowger</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Durable Mechanical Circulatory Support: JACC Scientific Statement</dc:title>
<dc:identifier>pmid:37758441</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.019</dc:identifier>
</item>
<item>
<title>Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758440/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>Many randomized trials in cardiovascular disease have repeat nonfatal events (such as hospitalizations) occurring during patient follow-up; yet, it remains common practice to have time-to-first event as the primary outcome. We explore the value of analyses that include repeat events. Do they help us understand the effect of treatment and total disease burden? Do they enhance statistical power? Should they become a trial's primary analysis? It may also be difficult to choose which of the various...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1445-1463. doi: 10.1016/j.jacc.2023.07.024.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Many randomized trials in cardiovascular disease have repeat nonfatal events (such as hospitalizations) occurring during patient follow-up; yet, it remains common practice to have time-to-first event as the primary outcome. We explore the value of analyses that include repeat events. Do they help us understand the effect of treatment and total disease burden? Do they enhance statistical power? Should they become a trial's primary analysis? It may also be difficult to choose which of the various statistical methods for analyzing repeat events to use, and we provide a nontechnical guide to what each method is doing. We compare several methods for repeat events: Lin Wei Yang Ying, negative binomial, joint frailty, win ratio, and area under the curve. We illustrate their performance in 5 large cardiovascular trials and compare them with time-to-first-event analyses. We review their use in recently published heart failure trials and make recommendations for their use in future trials.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758440/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758440</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.024>10.1016/j.jacc.2023.07.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758440</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>John Gregson</dc:creator>
<dc:creator>Gregg W Stone</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:creator>Milton Packer</dc:creator>
<dc:creator>Stefan D Anker</dc:creator>
<dc:creator>Cordula Zeller</dc:creator>
<dc:creator>Bjorn Redfors</dc:creator>
<dc:creator>Stuart J Pocock</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Recurrent Events in Cardiovascular Trials: JACC State-of-the-Art Review</dc:title>
<dc:identifier>pmid:37758440</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.024</dc:identifier>
</item>
<item>
<title>Hybrid Palliation for Critical Left Heart Obstruction Is Versatile: Risk Factors Still Impede Optimal Outcome</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758439/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1442-1444. doi: 10.1016/j.jacc.2023.08.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758439/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758439</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.023>10.1016/j.jacc.2023.08.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758439</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jonathan J Rome</dc:creator>
<dc:creator>Michael L O'Byrne</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Hybrid Palliation for Critical Left Heart Obstruction Is Versatile: Risk Factors Still Impede Optimal Outcome</dc:title>
<dc:identifier>pmid:37758439</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.023</dc:identifier>
</item>
<item>
<title>Outcomes After Hybrid Palliation for Infants With Critical Left Heart Obstruction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758438/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Mortality remains high after hybrid palliation for infants with critical left heart obstruction. Nonetheless, hybrid palliation may facilitate biventricular repair for some infants and for others may serve as stabilization for intended functional univentricular palliation or primary transplantation.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1427-1441. doi: 10.1016/j.jacc.2023.07.020.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Hybrid palliation (bilateral pulmonary artery banding with or without ductal stenting) is an initial management strategy for infants with critical left heart obstruction and serves as palliation until subsequent operations are pursued.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to determine patient characteristics and factors associated with subsequent outcomes for infants who underwent hybrid palliation.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: From 2005 to 2019, 214 of 1,236 prospectively enrolled infants within the Congenital Heart Surgeons' Society's critical left heart obstruction cohort underwent hybrid palliation across 24 institutions. Multivariable hazard modeling with competing risk methodology was performed to determine risk and factors associated with outcomes of biventricular repair, Fontan procedure, transplantation, or death.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Preoperative comorbidities (eg, prematurity, low birth weight, genetic syndrome) were identified in 70% of infants (150 of 214). Median follow-up was 7 years, ranging up to 17 years. Overall 12-year survival was 55%. At 5 years after hybrid palliation, 9% had biventricular repair, 36% had Fontan procedure, 12% had transplantation, 35% died without surgical endpoints, and 8% were alive without an endpoint. Factors associated with transplantation were absence of ductal stent, older age, absent interatrial communication, smaller aortic root size, larger tricuspid valve area z-score, and larger left ventricular volume. Factors associated with death were low birth weight, concomitant genetic syndrome, cardiopulmonary bypass use during hybrid palliation, moderate to severe tricuspid valve regurgitation, and smaller ascending aortic size.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Mortality remains high after hybrid palliation for infants with critical left heart obstruction. Nonetheless, hybrid palliation may facilitate biventricular repair for some infants and for others may serve as stabilization for intended functional univentricular palliation or primary transplantation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758438/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758438</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.020>10.1016/j.jacc.2023.07.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758438</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Madison B Argo</dc:creator>
<dc:creator>David J Barron</dc:creator>
<dc:creator>Pirooz Eghtesady</dc:creator>
<dc:creator>Can Yerebakan</dc:creator>
<dc:creator>Williams M DeCampli</dc:creator>
<dc:creator>Bahaaldin Alsoufi</dc:creator>
<dc:creator>Osami Honjo</dc:creator>
<dc:creator>Jeffrey P Jacobs</dc:creator>
<dc:creator>Tharini Paramananthan</dc:creator>
<dc:creator>Maha Rahman</dc:creator>
<dc:creator>Linda M Lambert</dc:creator>
<dc:creator>Anusha Jegatheeswaran</dc:creator>
<dc:creator>Sergio A Carrillo</dc:creator>
<dc:creator>S Adil Husain</dc:creator>
<dc:creator>Karthik Ramakrishnan</dc:creator>
<dc:creator>Christopher A Caldarone</dc:creator>
<dc:creator>Tara Karamlou</dc:creator>
<dc:creator>Jennifer Nelson</dc:creator>
<dc:creator>Chelsea Mannie</dc:creator>
<dc:creator>Jennifer C Romano</dc:creator>
<dc:creator>Joseph W Turek</dc:creator>
<dc:creator>Eugene H Blackstone</dc:creator>
<dc:creator>Mark E Galantowicz</dc:creator>
<dc:creator>James K Kirklin</dc:creator>
<dc:creator>Michael E Mitchell</dc:creator>
<dc:creator>Brian W McCrindle</dc:creator>
<dc:creator>Congenital Heart Surgeons Society Critical Left Heart Obstruction Work Group</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Outcomes After Hybrid Palliation for Infants With Critical Left Heart Obstruction</dc:title>
<dc:identifier>pmid:37758438</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.020</dc:identifier>
</item>
<item>
<title>A Genetic Dissection of Vascular Risk Factors for Cervical Artery Dissection: Under Pressure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758437/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1424-1426. doi: 10.1016/j.jacc.2023.08.011.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758437/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758437</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.011>10.1016/j.jacc.2023.08.011</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758437</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Tine De Backer</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>A Genetic Dissection of Vascular Risk Factors for Cervical Artery Dissection: Under Pressure</dc:title>
<dc:identifier>pmid:37758437</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.011</dc:identifier>
</item>
<item>
<title>Genetic Insights on the Relation of Vascular Risk Factors and Cervical Artery Dissection</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758436/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: These results are supportive of a causal association between higher BP and increased CeAD risk and recurrence and provide genetic evidence for lower CeAD risk under β-blockers. This may inform secondary prevention strategies and trial design for CeAD.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1411-1423. doi: 10.1016/j.jacc.2023.07.021.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The association between vascular risk factors and cervical artery dissections (CeADs), a leading cause of ischemic stroke (IS) in the young, remains controversial.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aimed to explore the causal relation of vascular risk factors with CeAD risk and recurrence and compare it to their relation with non-CeAD IS.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This study used 2-sample Mendelian randomization analyses to explore the association of blood pressure (BP), lipid levels, type 2 diabetes, waist-to-hip ratio, smoking, and body mass index with CeAD and non-CeAD IS. To simulate effects of the most frequently used BP-lowering drugs, this study constructed genetic proxies and tested their association with CeAD and non-CeAD IS. In analyses among patients with CeAD, the investigators studied the association between weighted genetic risk scores of vascular risk factors and the risk of multiple or early recurrent dissections.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Genetically determined higher systolic BP (OR: 1.51; 95% CI: 1.32-1.72) and diastolic BP (OR: 2.40; 95% CI: 1.92-3.00) increased the risk of CeAD (P &lt; 0.0001). Genetically determined higher body mass index was inconsistently associated with a lower risk of CeAD. Genetic proxies for β-blocker effects were associated with a lower risk of CeAD (OR: 0.65; 95% CI: 0.50-0.85), whereas calcium-channel blockers were associated with a lower risk of non-CeAD IS (OR: 0.75; 95% CI: 0.63-0.90). Weighted genetic risk scores for systolic BP and diastolic BP were associated with an increased risk of multiple or early recurrent CeAD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results are supportive of a causal association between higher BP and increased CeAD risk and recurrence and provide genetic evidence for lower CeAD risk under β-blockers. This may inform secondary prevention strategies and trial design for CeAD.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758436/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758436</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.021>10.1016/j.jacc.2023.07.021</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758436</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Quentin Le Grand</dc:creator>
<dc:creator>Leslie Ecker Ferreira</dc:creator>
<dc:creator>Tiina M Metso</dc:creator>
<dc:creator>Sabrina Schilling</dc:creator>
<dc:creator>Turgut Tatlisumak</dc:creator>
<dc:creator>Caspar Grond-Ginsbach</dc:creator>
<dc:creator>Stefan T Engelter</dc:creator>
<dc:creator>Philippe Lyrer</dc:creator>
<dc:creator>Jennifer J Majersik</dc:creator>
<dc:creator>Bradford B Worrall</dc:creator>
<dc:creator>Andrew M Southerland</dc:creator>
<dc:creator>Hugh S Markus</dc:creator>
<dc:creator>Mark Lathrop</dc:creator>
<dc:creator>Vincent Thijs</dc:creator>
<dc:creator>Didier Leys</dc:creator>
<dc:creator>Philippe Amouyel</dc:creator>
<dc:creator>Jean Dallongeville</dc:creator>
<dc:creator>Martin Dichgans</dc:creator>
<dc:creator>Alessandro Pezzini</dc:creator>
<dc:creator>Anna Bersano</dc:creator>
<dc:creator>Muralidharan Sargurupremraj</dc:creator>
<dc:creator>Stéphanie Debette</dc:creator>
<dc:creator>CADISP Consortium</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Genetic Insights on the Relation of Vascular Risk Factors and Cervical Artery Dissection</dc:title>
<dc:identifier>pmid:37758436</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.021</dc:identifier>
</item>
<item>
<title>Risk Estimation in Valvular Heart Disease in Pregnancy: An Idea Whose Time Has Come</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758435/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1407-1410. doi: 10.1016/j.jacc.2023.08.022.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758435/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758435</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.022>10.1016/j.jacc.2023.08.022</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758435</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Garima Sharma</dc:creator>
<dc:creator>Aditya Mehta</dc:creator>
<dc:creator>Nandita S Scott</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Risk Estimation in Valvular Heart Disease in Pregnancy: An Idea Whose Time Has Come</dc:title>
<dc:identifier>pmid:37758435</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.022</dc:identifier>
</item>
<item>
<title>Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758434/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: In pregnant patients with VHD, DEVI and CARPREG-II scores showed good discriminative ability and clinical utility across a range of probabilities. The DEVI score showed better agreement between predicted probabilities and observed events.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1395-1406. doi: 10.1016/j.jacc.2023.07.023.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Most risk stratification tools for pregnant patients with heart disease were developed in high-income countries and in populations with predominantly congenital heart disease, and therefore, may not be generalizable to those with valvular heart disease (VHD).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: The purpose of this study was to validate and establish the clinical utility of 2 risk stratification tools-DEVI (VHD-specific tool) and CARPREG-II-for predicting adverse cardiac events in pregnant patients with VHD.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We conducted a cohort study involving consecutive pregnancies complicated with VHD admitted to a tertiary center in a middle-income setting from January 2019 to April 2022. Individual risk for adverse composite cardiac events was calculated using DEVI and CARPREG-II models. Performance was assessed through discrimination and calibration characteristics. Clinical utility was evaluated with Decision Curve Analysis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 577 eligible pregnancies, 69 (12.1%) experienced a component of the composite outcome. A majority (94.7%) had rheumatic etiology, with mitral regurgitation as the predominant lesion (48.2%). The area under the receiver-operating characteristic curve was 0.884 (95% CI: 0.844-0.923) for the DEVI and 0.808 (95% CI: 0.753-0.863) for the CARPREG-II models. Calibration plots suggested that DEVI score overestimates risk at higher probabilities, whereas CARPREG-II score overestimates risk at both extremes and underestimates risk at middle probabilities. Decision curve analysis demonstrated that both models were useful across predicted probability thresholds between 10% and 50%.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In pregnant patients with VHD, DEVI and CARPREG-II scores showed good discriminative ability and clinical utility across a range of probabilities. The DEVI score showed better agreement between predicted probabilities and observed events.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758434/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758434</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.023>10.1016/j.jacc.2023.07.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758434</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Swaraj Nandini Pande</dc:creator>
<dc:creator>J Yavana Suriya</dc:creator>
<dc:creator>Sachit Ganapathy</dc:creator>
<dc:creator>Ajith Ananthakrishna Pillai</dc:creator>
<dc:creator>Santhosh Satheesh</dc:creator>
<dc:creator>Nivedita Mondal</dc:creator>
<dc:creator>K T Harichandra Kumar</dc:creator>
<dc:creator>Candice Silversides</dc:creator>
<dc:creator>Samuel C Siu</dc:creator>
<dc:creator>Rohan D'Souza</dc:creator>
<dc:creator>Anish Keepanasseril</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Validation of Risk Stratification for Cardiac Events in Pregnant Women With Valvular Heart Disease</dc:title>
<dc:identifier>pmid:37758434</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.023</dc:identifier>
</item>
<item>
<title>The Promise of Primary Prevention in Older Adults</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758433/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1392-1394. doi: 10.1016/j.jacc.2023.08.005.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758433/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758433</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.08.005>10.1016/j.jacc.2023.08.005</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758433</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Safi U Khan</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>The Promise of Primary Prevention in Older Adults</dc:title>
<dc:identifier>pmid:37758433</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.08.005</dc:identifier>
</item>
<item>
<title>LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758432/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Our study supports a relative clinical benefit of lowering LDL cholesterol for primary prevention of major vascular events in individuals aged ≥70 years similarly as in individuals aged &lt;70 years.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2023 Oct 3;82(14):1381-1391. doi: 10.1016/j.jacc.2023.07.027.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Reducing low-density lipoprotein (LDL) cholesterol with lipid-lowering therapy has consistently been shown to lower the risk of cardiovascular disease in primary prevention trials where the majority of individuals are aged &lt;70 years. For older individuals, however, evidence is less clear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: In this study, the authors sought to compare the clinical effectiveness of lowering LDL cholesterol by means of lipid-lowering therapy for primary prevention of cardiovascular disease among older and younger individuals in a Danish nationwide cohort.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We included individuals aged ≥50 years who had initiated lipid-lowering therapy from January 1, 2008, to October 31, 2017, had no history of atherosclerotic cardiovascular disease, and had a baseline and a within-1-year LDL cholesterol measurement. We assessed the associated risk of major vascular events among older individuals (≥70 years) by HRs per 1 mmol/L reduction in LDL cholesterol compared with younger individuals (&lt;70 years).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: For both the 16,035 older and the 49,155 younger individuals, the median LDL cholesterol reduction was 1.7 mmol/L. Each 1 mmol/L reduction in LDL cholesterol in older individuals was significantly associated with a 23% lower risk of major vascular events (HR: 0.77; 95% CI: 0.71-0.83), which was equal to that of younger individuals (HR: 0.76; 95% CI: 0.71-0.80; P value for difference = 0.79). Similar results were observed across all secondary analyses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study supports a relative clinical benefit of lowering LDL cholesterol for primary prevention of major vascular events in individuals aged ≥70 years similarly as in individuals aged &lt;70 years.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758432/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758432</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2023.07.027>10.1016/j.jacc.2023.07.027</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758432</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Niklas Worm Andersson</dc:creator>
<dc:creator>Giulia Corn</dc:creator>
<dc:creator>Tine Lovsø Dohlmann</dc:creator>
<dc:creator>Mads Melbye</dc:creator>
<dc:creator>Jan Wohlfahrt</dc:creator>
<dc:creator>Marie Lund</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>LDL-C Reduction With Lipid-Lowering Therapy for Primary Prevention of Major Vascular Events Among Older Individuals</dc:title>
<dc:identifier>pmid:37758432</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2023.07.027</dc:identifier>
</item>
<item>
<title>Acquired cardiovascular disease in adults with congenital heart disease</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37758198/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>Rates of successful surgical repair and life expectancy for patients with congenital heart disease have increased dramatically in recent decades. Thanks to advances in diagnosis, treatment, and follow-up care, an ever-increasing number of individuals with congenital heart disease are reaching advanced age. The exposure to cardiovascular risk factors during their lifetime is modifying the outlook and late clinical trajectory of adult congenital heart disease (ACHD). Their disease burden is...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 27:ehad570. doi: 10.1093/eurheartj/ehad570. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Rates of successful surgical repair and life expectancy for patients with congenital heart disease have increased dramatically in recent decades. Thanks to advances in diagnosis, treatment, and follow-up care, an ever-increasing number of individuals with congenital heart disease are reaching advanced age. The exposure to cardiovascular risk factors during their lifetime is modifying the outlook and late clinical trajectory of adult congenital heart disease (ACHD). Their disease burden is shifting from congenital to acquired, primarily atherosclerotic cardiovascular disease (ASCVD) with worrisome consequences. In addition, the complex background of ACHD often curbs appropriate preventive strategies by general practitioners or adult cardiologists. Comprehensive guidance for the prevention and management of acquired heart disease in ACHD patients is currently not available, as this topic has not been covered by the European Society of Cardiology (ESC) guidelines on cardiovascular disease prevention or the ESC guidelines for the management of ACHD. In this document, a state-of-the-art overview of acquired heart disease in ACHD patients and guidance on ASCVD prevention for both ACHD specialists and non-ACHD cardiologists are provided. The aim is to provide a clinical consensus statement to foster the development of a sustainable strategy for the prevention of ASCVD in a practical and simple-to-follow way in this ever-growing cardiovascular cohort, thus reducing their cardiovascular burden.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37758198/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37758198</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad570>10.1093/eurheartj/ehad570</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37758198</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Margarita Brida</dc:creator>
<dc:creator>Salvatore De Rosa</dc:creator>
<dc:creator>Antoine Legendre</dc:creator>
<dc:creator>Magalie Ladouceur</dc:creator>
<dc:creator>Laura Dos Subira</dc:creator>
<dc:creator>Giancarlo Scognamiglio</dc:creator>
<dc:creator>Carlo Di Mario</dc:creator>
<dc:creator>Jolien Roos-Hesselink</dc:creator>
<dc:creator>Eva Goossens</dc:creator>
<dc:creator>Gerhard Diller</dc:creator>
<dc:creator>Michael A Gatzoulis</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Acquired cardiovascular disease in adults with congenital heart disease</dc:title>
<dc:identifier>pmid:37758198</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad570</dc:identifier>
</item>
<item>
<title>Influence of autozygosity on common disease risk across the phenotypic spectrum</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37757828/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>Autozygosity is associated with rare Mendelian disorders and clinically relevant quantitative traits. We investigated associations between the fraction of the genome in runs of homozygosity (F(ROH)) and common diseases in Genes &amp; Health (n = 23,978 British South Asians), UK Biobank (n = 397,184), and 23andMe. We show that restricting analysis to offspring of first cousins is an effective way of reducing confounding due to social/environmental correlates of F(ROH). Within this group in G&amp;H+UK...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2023 Sep 20:S0092-8674(23)00918-2. doi: 10.1016/j.cell.2023.08.028. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autozygosity is associated with rare Mendelian disorders and clinically relevant quantitative traits. We investigated associations between the fraction of the genome in runs of homozygosity (F<sub>ROH</sub>) and common diseases in Genes &amp; Health (n = 23,978 British South Asians), UK Biobank (n = 397,184), and 23andMe. We show that restricting analysis to offspring of first cousins is an effective way of reducing confounding due to social/environmental correlates of F<sub>ROH</sub>. Within this group in G&amp;H+UK Biobank, we found experiment-wide significant associations between F<sub>ROH</sub> and twelve common diseases. We replicated associations with type 2 diabetes (T2D) and post-traumatic stress disorder via within-sibling analysis in 23andMe (median n = 480,282). We estimated that autozygosity due to consanguinity accounts for 5%-18% of T2D cases among British Pakistanis. Our work highlights the possibility of widespread non-additive genetic effects on common diseases and has important implications for global populations with high rates of consanguinity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37757828/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37757828</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2023.08.028>10.1016/j.cell.2023.08.028</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37757828</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Daniel S Malawsky</dc:creator>
<dc:creator>Eva van Walree</dc:creator>
<dc:creator>Benjamin M Jacobs</dc:creator>
<dc:creator>Teng Hiang Heng</dc:creator>
<dc:creator>Qin Qin Huang</dc:creator>
<dc:creator>Ataf H Sabir</dc:creator>
<dc:creator>Saadia Rahman</dc:creator>
<dc:creator>Saghira Malik Sharif</dc:creator>
<dc:creator>Ahsan Khan</dc:creator>
<dc:creator>Maša Umićević Mirkov</dc:creator>
<dc:creator>23andMe Research Team</dc:creator>
<dc:creator>Genes &amp; Health Research Team</dc:creator>
<dc:creator>Hiroyuki Kuwahara</dc:creator>
<dc:creator>Xin Gao</dc:creator>
<dc:creator>Fowzan S Alkuraya</dc:creator>
<dc:creator>Danielle Posthuma</dc:creator>
<dc:creator>William G Newman</dc:creator>
<dc:creator>Christopher J Griffiths</dc:creator>
<dc:creator>Rohini Mathur</dc:creator>
<dc:creator>David A van Heel</dc:creator>
<dc:creator>Sarah Finer</dc:creator>
<dc:creator>Jared O'Connell</dc:creator>
<dc:creator>Hilary C Martin</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Influence of autozygosity on common disease risk across the phenotypic spectrum</dc:title>
<dc:identifier>pmid:37757828</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2023.08.028</dc:identifier>
</item>
<item>
<title>Smoking and cardiovascular outcomes after percutaneous coronary intervention: a Korean study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS: Smoking is associated with a higher risk of adverse outcomes in patients undergoing PCI. Quitters after PCI with &lt;20 PYs were associated with a risk comparable with that of non-smokers.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2023 Sep 26:ehad616. doi: 10.1093/eurheartj/ehad616. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: The authors investigated the impact of smoking and its cessation after percutaneous coronary intervention (PCI) on cardiovascular outcomes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Using a nationwide database from the Korean National Health Insurance System, 74 471 patients undergoing PCI between 2009 and 2016 were classified as non-, ex-, or current smokers, depending on smoking status at the first health check-up within 1 year after PCI. The primary outcome was major adverse cardiovascular and cerebrovascular event (MACCE), a composite of all-cause death, myocardial infarction, coronary revascularization, and stroke.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: During 4.0 years of follow-up, current smokers had a 19.8% higher rate of MACCE than non-smokers [adjusted hazard ratio (aHR) 1.198; 95% confidence interval (CI) 1.137-1.263], and ex-smokers tended to have a comparable rate with that of non-smokers (aHR 1.036; 95% CI .992-1.081). For 31 887 patients with both pre- and post-PCI health check-up data, the effects of smoking cessation were analysed. Among quitters who stopped smoking after PCI, quitters with cumulative smoking exposure of &lt;20 pack-years (PYs) tended to have a comparable rate of MACCE with that of persistent non-smokers. However, the rate in quitters with cumulative exposure of ≥20 PYs was comparable with that of persistent smokers [aHR (95% CI) for &lt;10 PY, 1.182 (.971-1.438); 10-20 PYs 1.114 (.963-1.290); 20-30 PYs 1.206 (1.054-1.380); ≥ 30 PYs 1.227 (1.113-1.352); persistent smokers 1.223 (1.126-1.328), compared with persistent non-smokers, respectively, P for interaction &lt;.001].</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Smoking is associated with a higher risk of adverse outcomes in patients undergoing PCI. Quitters after PCI with &lt;20 PYs were associated with a risk comparable with that of non-smokers.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37757448/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37757448</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad616>10.1093/eurheartj/ehad616</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37757448</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>You-Jeong Ki</dc:creator>
<dc:creator>Kyungdo Han</dc:creator>
<dc:creator>Hyo-Soo Kim</dc:creator>
<dc:creator>Jung-Kyu Han</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Smoking and cardiovascular outcomes after percutaneous coronary intervention: a Korean study</dc:title>
<dc:identifier>pmid:37757448</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad616</dc:identifier>
</item>
<item>
<title>The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>CONCLUSIONS AND RELEVANCE: The results of this study indicate that addition of PWI to PVI did not improve freedom from arrhythmia recurrence or recovery of LVEF in patients with persistent AF and symptomatic HFrEF. Catheter ablation was associated with significant improvements in systolic function, irrespective of ablation strategy used. These results caution against the routine inclusion of PWI in patients with HFrEF undergoing first-time catheter ablation for persistent AF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3208. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">IMPORTANCE: Catheter ablation for patients with atrial fibrillation (AF) and heart failure with reduced ejection fraction (HFrEF) is associated with improved left ventricular ejection fraction (LVEF) and survival compared with medical therapy. Nonrandomized studies have reported improved success with posterior wall isolation (PWI).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVE: To determine the impact of pulmonary vein isolation (PVI) with PWI vs PVI alone on outcomes in patients with HFrEF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">DESIGN, SETTING, AND PARTICIPANTS: This was an ad hoc secondary analysis of the CAPLA trial, a multicenter, prospective, randomized control trial that involved 11 centers in 3 countries (Australia, Canada, and UK). CAPLA featured 338 patients with persistent AF randomized to either PVI plusPWI or PVI alone. This substudy included patients in the original CAPLA study who had symptomatic HFrEF (LVEF &lt;50% and New York Heart Association class ≥II).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">INTERVENTIONS: Pulmonary vein isolation with PWI vs PVI alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">MAIN OUTCOMES AND MEASURES: The primary end point was freedom from any documented atrial arrhythmia greater than 30 seconds, after a single ablation procedure, without the use of antiarrhythmic drug (AAD) therapy at 12 months.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 98 patients with persistent AF and symptomatic HFrEF were identified (mean [SD] age, 62.1 [9.8] years; 79.5% men; and mean [SD] LVEF at baseline, 34.6% [7.9%]). After 12 months, 58.7% of patients with PVI plus PWI were free from recurrent atrial arrhythmia without the use of AAD therapy vs 61.5% with PVI alone (hazard ratio, 1.02; 95% CI, 0.54-1.91; P = .96). There were no significant differences in freedom from atrial arrhythmia with or without AAD therapy after multiple procedures (PVI plus PWI vs PVI alone, 60.9% vs 65.4%; P = .73) or AF burden (median, 0% in both groups; P = .78). Mean LVEF improved substantially in PVI plus PWI (∆ LVEF, 19.3% [13.0%; P &lt; .01) and PVI alone (18.2% [14.1%; P &lt; .01), with no difference between groups (P = .71). Normalization of LV function occurred in 65.2% of patients in the PVI plus PWI group and 50.0% of patients with PVI alone (P = .13).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS AND RELEVANCE: The results of this study indicate that addition of PWI to PVI did not improve freedom from arrhythmia recurrence or recovery of LVEF in patients with persistent AF and symptomatic HFrEF. Catheter ablation was associated with significant improvements in systolic function, irrespective of ablation strategy used. These results caution against the routine inclusion of PWI in patients with HFrEF undergoing first-time catheter ablation for persistent AF.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">TRIAL REGISTRATION: http://anzctr.org.au Identifier: ACTRN12616001436460.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37755920/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37755920</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3208>10.1001/jamacardio.2023.3208</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37755920</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Jeremy William</dc:creator>
<dc:creator>David Chieng</dc:creator>
<dc:creator>Hariharan Sugumar</dc:creator>
<dc:creator>Liang-Han Ling</dc:creator>
<dc:creator>Louise Segan</dc:creator>
<dc:creator>Rose Crowley</dc:creator>
<dc:creator>Ahmed Al-Kaisey</dc:creator>
<dc:creator>Joshua Hawson</dc:creator>
<dc:creator>Sandeep Prabhu</dc:creator>
<dc:creator>Aleksandr Voskoboinik</dc:creator>
<dc:creator>Geoffrey Wong</dc:creator>
<dc:creator>Joseph B Morton</dc:creator>
<dc:creator>Geoffrey Lee</dc:creator>
<dc:creator>Alex J McLellan</dc:creator>
<dc:creator>Michael Wong</dc:creator>
<dc:creator>Rajeev K Pathak</dc:creator>
<dc:creator>Laurence Sterns</dc:creator>
<dc:creator>Matthew Ginks</dc:creator>
<dc:creator>Christopher M Reid</dc:creator>
<dc:creator>Prashanthan Sanders</dc:creator>
<dc:creator>Jonathan M Kalman</dc:creator>
<dc:creator>Peter M Kistler</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>The Role of Posterior Wall Isolation in Catheter Ablation for Persistent Atrial Fibrillation and Systolic Heart Failure: A Secondary Analysis of a Randomized Clinical Trial</dc:title>
<dc:identifier>pmid:37755920</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3208</dc:identifier>
</item>
<item>
<title>Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20230928203712&amp;v=2.17.9.post6+86293ac
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">JAMA Cardiol. 2023 Sep 27. doi: 10.1001/jamacardio.2023.3223. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/37755820/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20230928203712&v=2.17.9.post6+86293ac">37755820</a> | DOI:<a href=https://doi.org/10.1001/jamacardio.2023.3223>10.1001/jamacardio.2023.3223</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:37755820</guid>
<pubDate>Wed, 27 Sep 2023 06:00:00 -0400</pubDate>
<dc:creator>Laura P Cohen</dc:creator>
<dc:creator>Brandon K Bellows</dc:creator>
<dc:date>2023-09-27</dc:date>
<dc:source>JAMA cardiology</dc:source>
<dc:title>Economic Evaluation of Angiotensin-Neprilysin Inhibitors Across Ejection Fractions</dc:title>
<dc:identifier>pmid:37755820</dc:identifier>
<dc:identifier>doi:10.1001/jamacardio.2023.3223</dc:identifier>
</item>





























</channel>
</rss>